Cargando…

Markers for Detection of Prostate Cancer

Early detection of prostate cancer is problematic, not just because of uncertainly whether a diagnosis will benefit an individual patient, but also as a result of the imprecise and invasive nature of establishing a diagnosis by biopsy. Despite its low sensitivity and specificity for identifying pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Clarke, Raymond A., Schirra, Horst J., Catto, James W., Lavin, Martin F., Gardiner, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835122/
https://www.ncbi.nlm.nih.gov/pubmed/24281110
http://dx.doi.org/10.3390/cancers2021125
_version_ 1782292105006153728
author Clarke, Raymond A.
Schirra, Horst J.
Catto, James W.
Lavin, Martin F.
Gardiner, Robert A.
author_facet Clarke, Raymond A.
Schirra, Horst J.
Catto, James W.
Lavin, Martin F.
Gardiner, Robert A.
author_sort Clarke, Raymond A.
collection PubMed
description Early detection of prostate cancer is problematic, not just because of uncertainly whether a diagnosis will benefit an individual patient, but also as a result of the imprecise and invasive nature of establishing a diagnosis by biopsy. Despite its low sensitivity and specificity for identifying patients harbouring prostate cancer, serum prostate specific antigen (PSA) has become established as the most reliable and widely-used diagnostic marker for this condition. In its wake, many other markers have been described and evaluated. This review focuses on the supporting evidence for the most prominent of these for detection and also for predicting outcome in prostate cancer.
format Online
Article
Text
id pubmed-3835122
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-38351222013-11-21 Markers for Detection of Prostate Cancer Clarke, Raymond A. Schirra, Horst J. Catto, James W. Lavin, Martin F. Gardiner, Robert A. Cancers (Basel) Review Early detection of prostate cancer is problematic, not just because of uncertainly whether a diagnosis will benefit an individual patient, but also as a result of the imprecise and invasive nature of establishing a diagnosis by biopsy. Despite its low sensitivity and specificity for identifying patients harbouring prostate cancer, serum prostate specific antigen (PSA) has become established as the most reliable and widely-used diagnostic marker for this condition. In its wake, many other markers have been described and evaluated. This review focuses on the supporting evidence for the most prominent of these for detection and also for predicting outcome in prostate cancer. MDPI 2010-06-04 /pmc/articles/PMC3835122/ /pubmed/24281110 http://dx.doi.org/10.3390/cancers2021125 Text en © 2010 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Clarke, Raymond A.
Schirra, Horst J.
Catto, James W.
Lavin, Martin F.
Gardiner, Robert A.
Markers for Detection of Prostate Cancer
title Markers for Detection of Prostate Cancer
title_full Markers for Detection of Prostate Cancer
title_fullStr Markers for Detection of Prostate Cancer
title_full_unstemmed Markers for Detection of Prostate Cancer
title_short Markers for Detection of Prostate Cancer
title_sort markers for detection of prostate cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835122/
https://www.ncbi.nlm.nih.gov/pubmed/24281110
http://dx.doi.org/10.3390/cancers2021125
work_keys_str_mv AT clarkeraymonda markersfordetectionofprostatecancer
AT schirrahorstj markersfordetectionofprostatecancer
AT cattojamesw markersfordetectionofprostatecancer
AT lavinmartinf markersfordetectionofprostatecancer
AT gardinerroberta markersfordetectionofprostatecancer